drugset
drugset / Trial / NCT02675049

Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia

NCT02675049 ↗

Phase 2 Completed 100 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is going to evaluate the safety and effectiveness of intranasal DEX(dexmedetomidine) in breast lumpectomy under local anaesthesia,and to investigate the optimal dose of intranasal DEX in breast lumpectomy.

Timeline

Start
2016-01
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1 ug/kg Intranasal
Subject Dexmedetomidine Other / unclassified 1.5 ug/kg Intranasal
Subject Dexmedetomidine Other / unclassified 2 ug/kg Intranasal

Indications

No indication recorded.